Fmr LLC Buys 101,182 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

FMR LLC grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 1.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,329,902 shares of the company's stock after purchasing an additional 101,182 shares during the period. FMR LLC owned approximately 9.35% of Harmony Biosciences worth $183,402,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in HRMY. Hillsdale Investment Management Inc. increased its position in shares of Harmony Biosciences by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock valued at $2,340,000 after acquiring an additional 300 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in shares of Harmony Biosciences by 2.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock valued at $704,000 after purchasing an additional 420 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after buying an additional 436 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Harmony Biosciences by 28.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after buying an additional 519 shares during the last quarter. Finally, Aviva PLC lifted its stake in Harmony Biosciences by 3.9% during the 4th quarter. Aviva PLC now owns 18,072 shares of the company's stock valued at $622,000 after acquiring an additional 686 shares during the period. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY traded up $0.52 during trading on Friday, hitting $28.46. 456,319 shares of the company's stock were exchanged, compared to its average volume of 573,192. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company has a market cap of $1.63 billion, a price-to-earnings ratio of 13.49, a PEG ratio of 0.47 and a beta of 0.80. The business's 50-day simple moving average is $33.11 and its 200 day simple moving average is $34.53.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.11. The firm had revenue of $201.30 million during the quarter, compared to analyst estimates of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences's revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.45 earnings per share. As a group, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total value of $44,920.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total value of $774,228.09. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,945 shares of company stock valued at $2,442,815. 30.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on HRMY shares. Needham & Company LLC restated a "buy" rating and set a $50.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and set a $70.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price on the stock. Finally, Mizuho raised their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a report on Tuesday, March 18th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences currently has a consensus rating of "Buy" and an average target price of $53.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.